BALLERUP, Denmark-LEO Pharma, a worldwide leader in scientific dermatology, announced that Gitte Aabo will step down as President and CEO after 27 years within the enterprise, 11 of those as CEO. The Board of Directors has appointed Catherine Mazzacco as the new President and CEO effective August 1, 2019.
LEO Pharma has embarked on a bold approach closer to 2025 and has, during the latest years, succeeded in constructing a robust R&D pipeline and an appreciably accelerated worldwide footprint. The subsequent section in the corporation’s method is to prepare the launch of several innovative remedies, and the Board of Directors and Gitte Aabo have at the same time concluded that this is the right time to make a management alternative to keep the successful route of LEO Pharma.
Olivier Bohuon, Chairman of LEO Pharma Board of Directors, commented: “I would like to thank Gitte Aabo for having carried out a remarkable job in growing LEO Pharma from a small European business enterprise into a global leader in scientific dermatology, and for appearing as a leader in affected person centricity. Her contribution to the continuing fulfillment of the business enterprise has been virtually superb.”
Gitte Aabo stated: “Our consciousness on assisting human beings to gain healthy pores and skin and our 2025 approach have set LEO Pharma on a brand new trajectory. This is the proper time to hand over to a successor who will oversee the approaching product launches and comfy the long-term achievement of LEO Pharma. I am very grateful for having had the possibility to assist patients at some point in my career at LEO Pharma, and for having labored with such great humans. I am pleased with what we’ve got carried out together and with the organization, I pass it directly to my successor.”
LEO Pharma’s Board of Directors has appointed Catherine Mazzacco as the President and CEO, from August 1, 2019. Catherine Mazzacco is a performing executive with more than 25 years of experience in international commercial enterprise management, strategy, marketing, and sales in the pharmaceutical and life-science industry, which includes launching and expanding biologics in immunology. Her wealth of professional and commercial enterprise experience includes positions as head of Global Commercial Operations for GE Healthcare’s BioPharma division, and, earlier than that, several leadership positions at Abbott within the pharmaceutical, diagnostic, and medical devices divisions.
